These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 25706475)

  • 1. Nuclear export inhibitors avert progression in preclinical models of inflammatory demyelination.
    Haines JD; Herbin O; de la Hera B; Vidaurre OG; Moy GA; Sun Q; Fung HY; Albrecht S; Alexandropoulos K; McCauley D; Chook YM; Kuhlmann T; Kidd GJ; Shacham S; Casaccia P
    Nat Neurosci; 2015 Apr; 18(4):511-20. PubMed ID: 25706475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.
    Green AL; Ramkissoon SH; McCauley D; Jones K; Perry JA; Hsu JH; Ramkissoon LA; Maire CL; Hubbell-Engler B; Knoff DS; Shacham S; Ligon KL; Kung AL
    Neuro Oncol; 2015 May; 17(5):697-707. PubMed ID: 25366336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds.
    Crochiere ML; Baloglu E; Klebanov B; Donovan S; Del Alamo D; Lee M; Kauffman M; Shacham S; Landesman Y
    Oncotarget; 2016 Jan; 7(2):1863-77. PubMed ID: 26654943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.
    Ranganathan P; Yu X; Na C; Santhanam R; Shacham S; Kauffman M; Walker A; Klisovic R; Blum W; Caligiuri M; Croce CM; Marcucci G; Garzon R
    Blood; 2012 Aug; 120(9):1765-73. PubMed ID: 22677130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.
    De Cesare M; Cominetti D; Doldi V; Lopergolo A; Deraco M; Gandellini P; Friedlander S; Landesman Y; Kauffman MG; Shacham S; Pennati M; Zaffaroni N
    Oncotarget; 2015 May; 6(15):13119-32. PubMed ID: 25948791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel reversible selective inhibitor of nuclear export shows that CRM1 is a target in colorectal cancer cells.
    Niu M; Chong Y; Han Y; Liu X
    Cancer Biol Ther; 2015; 16(7):1110-8. PubMed ID: 25996664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ratjadone and leptomycin B block CRM1-dependent nuclear export by identical mechanisms.
    Meissner T; Krause E; Vinkemeier U
    FEBS Lett; 2004 Oct; 576(1-2):27-30. PubMed ID: 15474004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of HDAC nuclear export and cardiomyocyte hypertrophy by novel irreversible inhibitors of CRM1.
    Monovich L; Koch KA; Burgis R; Osimboni E; Mann T; Wall D; Gao J; Feng Y; Vega RB; Turner BA; Hood DB; Law A; Papst PJ; Koditek D; Chapo JA; Reid BG; Melvin LS; Pagratis NC; McKinsey TA
    Biochim Biophys Acta; 2009 May; 1789(5):422-31. PubMed ID: 19414071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of CRM1-mediated nuclear export of influenza A nucleoprotein and nuclear export protein as a novel target for antiviral drug development.
    Chutiwitoonchai N; Mano T; Kakisaka M; Sato H; Kondoh Y; Osada H; Kotani O; Yokoyama M; Sato H; Aida Y
    Virology; 2017 Jul; 507():32-39. PubMed ID: 28399435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276.
    Schmidt J; Braggio E; Kortuem KM; Egan JB; Zhu YX; Xin CS; Tiedemann RE; Palmer SE; Garbitt VM; McCauley D; Kauffman M; Shacham S; Chesi M; Bergsagel PL; Stewart AK
    Leukemia; 2013 Dec; 27(12):2357-65. PubMed ID: 23752175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type 1 parathyroid hormone receptor (PTH1R) nuclear trafficking: regulation of PTH1R nuclear-cytoplasmic shuttling by importin-alpha/beta and chromosomal region maintenance 1/exportin 1.
    Pickard BW; Hodsman AB; Fraher LJ; Watson PH
    Endocrinology; 2007 May; 148(5):2282-9. PubMed ID: 17317770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia.
    Lapalombella R; Sun Q; Williams K; Tangeman L; Jha S; Zhong Y; Goettl V; Mahoney E; Berglund C; Gupta S; Farmer A; Mani R; Johnson AJ; Lucas D; Mo X; Daelemans D; Sandanayaka V; Shechter S; McCauley D; Shacham S; Kauffman M; Chook YM; Byrd JC
    Blood; 2012 Nov; 120(23):4621-34. PubMed ID: 23034282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The nucleoporin Nup214 sequesters CRM1 at the nuclear rim and modulates NFkappaB activation in Drosophila.
    Xylourgidis N; Roth P; Sabri N; Tsarouhas V; Samakovlis C
    J Cell Sci; 2006 Nov; 119(Pt 21):4409-19. PubMed ID: 17032737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.
    Etchin J; Sanda T; Mansour MR; Kentsis A; Montero J; Le BT; Christie AL; McCauley D; Rodig SJ; Kauffman M; Shacham S; Stone R; Letai A; Kung AL; Thomas Look A
    Br J Haematol; 2013 Apr; 161(1):117-27. PubMed ID: 23373539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear proteasomal degradation and cytoplasmic retention underlie early nuclear exclusion of transcription factor Max upon axon damage.
    Petrs-Silva H; Chiarini LB; Linden R
    Exp Neurol; 2008 Sep; 213(1):202-9. PubMed ID: 18601921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A.
    Miyake T; Pradeep S; Wu SY; Rupaimoole R; Zand B; Wen Y; Gharpure KM; Nagaraja AS; Hu W; Cho MS; Dalton HJ; Previs RA; Taylor ML; Hisamatsu T; Kang Y; Liu T; Shacham S; McCauley D; Hawke DH; Wiktorowicz JE; Coleman RL; Sood AK
    Clin Cancer Res; 2015 Jul; 21(14):3286-97. PubMed ID: 25878333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expanded polyglutamine domain possesses nuclear export activity which modulates subcellular localization and toxicity of polyQ disease protein via exportin-1.
    Chan WM; Tsoi H; Wu CC; Wong CH; Cheng TC; Li HY; Lau KF; Shaw PC; Perrimon N; Chan HY
    Hum Mol Genet; 2011 May; 20(9):1738-50. PubMed ID: 21300695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity.
    Sakakibara K; Saito N; Sato T; Suzuki A; Hasegawa Y; Friedman JM; Kufe DW; Vonhoff DD; Iwami T; Kawabe T
    Blood; 2011 Oct; 118(14):3922-31. PubMed ID: 21841164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia.
    Vercruysse T; De Bie J; Neggers JE; Jacquemyn M; Vanstreels E; Schmid-Burgk JL; Hornung V; Baloglu E; Landesman Y; Senapedis W; Shacham S; Dagklis A; Cools J; Daelemans D
    Clin Cancer Res; 2017 May; 23(10):2528-2541. PubMed ID: 27780859
    [No Abstract]   [Full Text] [Related]  

  • 20. CRM1 as a new therapeutic target for non-Hodgkin lymphoma.
    Han X; Wang J; Shen Y; Zhang N; Wang S; Yao J; Shi Y
    Leuk Res; 2015 Jan; 39(1):38-46. PubMed ID: 25466285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.